Zivo Bioscience (NASDAQ: ZIVO) recently announced the signing of a landmark commercial-scale manufacturing agreement with Cyanotech, to jointly advance the large-scale production of its patented Zivolife™ algae biomass product.

This agreement marks a significant step for Zivo Bioscience in turning laboratory research results into commercial products, laying a solid foundation for future market expansion. According to the terms of the agreement, Cyanotech will use its advanced microalgae cultivation facilities in Hawaii to provide Zivo Bioscience with large-scale production services that meet current Good Manufacturing Practice (cGMP) standards. Zivolife™, as a specialty algae biomass rich in bioactive components, has broad application prospects in nutritional supplements, functional foods, and animal health sectors. This collaboration not only demonstrates the synergistic effects between both parties in the microalgae technology field, but also highlights Zivo Bioscience's clear path to accelerating product commercialization through strategic partnerships. With production capacity now secured, the company is expected to bring the Zivolife™ product line to market more quickly, providing innovative solutions for the global health industry.